Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats

Toxicological Sciences

Volumn 110, Issue 2, 2009, Pages 255-269

  Punt, Ans ^a,b   Paini, Alicia ^a,b   Boersma, Marelle G ^a   Freidig, Andreas P ^c   Delatour, Thierry ^b   Scholz, Gabriele ^b   Schilter, Benoît ^b   van Bladeren, Peter J ^a,b   Rietjens, Ivonne M C M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c Amsterdam Molecular Therapeutics   (Netherlands)

Author keywords

Estragole; Human; In vitro; Metabolism; PBBK; Species differences

Indexed keywords

1' HYDROXYESTRAGOLE; 1' SULFOOXYESTRAGOLE; BENZENE DERIVATIVE; ESTRAGOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL MODEL; CONTROLLED STUDY; DETOXIFICATION; HUMAN; HUMAN CELL; LIVER METABOLISM; MALE; METABOLITE; NONHUMAN; OXIDATION; PREDICTION; RAT; TOXICOKINETICS; TOXIN ANALYSIS;

ANIMALS; ANISOLES; BIOTRANSFORMATION; CARCINOGENS; FEMALE; GLUCURONIDES; HUMANS; INTESTINE, SMALL; KIDNEY; LUNG; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MODELS, BIOLOGICAL; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; TOXICITY TESTS;

RATTUS;

EID: 67650727414     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp102     Document Type: Article

References (36)

1. Anthony, A., Caldwell, J., Hutt, A. J., and Smith, R. L. (1987). Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1′-hydroxyestragole. Food Chem. Toxicol. 25, 799-806.
2. Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R., Carlile, D. J., Edwards, R. J., Houston, J. B., Lake, B. G., Lipscomb, J. C., Pelkonen, O. R., et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45.
3. Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., and Beliles, R. P. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484.
4. DeJongh, J., Verhaar, H. J. M., and Hermens, J. L. M. (1997). A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 72, 17-25.
5. Drinkwater, N. R., Miller, E. C., Miller, J. A., and Pitot, H. C. (1976). Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1′-hydroxyestragole in the mouse and mutagenicity of 1#-acetoxyestragole in bacteria. J. Natl. Cancer Inst. 57, 1323-1331.
6. Evans, M. V., and Andersen, M. E. (2000). Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): Assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol. Sci. 54, 71-80.
7. Fisher, M. B., Campanale, K., Ackermann, B. L., VandenBranden, M., and Wrighton, S. A. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos. 28, 560-566.
8. Guenthner, T. M., and Luo, G. (2001). Investigation of the role of the 2′,3′-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Toxicology 160, 47-58.
9. Hissink, A. M., Van Ommen, B., Kruse, J., and Van Bladeren, P. J. (1997). A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. Toxicol. Appl. Pharmacol. 145, 301-310.
10. Ingelman-Sundberg, M., Oscarson, M., and McLellan, R. A. (1999). Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342-349.
11. Iyer, L. V., Ho, M. N., Shinn, W. M., Bradford, W. W., Tanga, M. J., Nath, S. S., and Green, C. E. (2003). Glucuronidation of 1′-hydroxyestragole (1′-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. Toxicol. Sci. 73, 36-43.
12. Jeurissen, S. M., Punt, A., Boersma, M. G., Bogaards, J. J. P., Fiamegos, Y. C., Schilter, B., Van Bladeren, P. J., Cnubben, N. H. P., and Rietjens, I. M. C. M. (2007). Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem. Res. Toxicol. 20, 798-806.
13. Jiang, Z., Dragin, N., Jorge-Nebert, L. F., Martin, M. V., Guengerich, F. P., Aklillu, E., Ingelman-Sundberg, M., Hammons, G. J., Lyn-Cook, B. D., Kadlubar, F. F., et al. (2006). Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics 16, 359-367.
14. Lam, C. W., Galen, T. J., Boyd, J. F., and Pierson, D. L. (1990). Mechanism of transport and distribution of organic solvents in blood. Toxicol. Appl. Pharmacol. 104, 117-129.
15. Lin, J. H., and Wong, B. K. (2002). Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr. Drug Metab. 3, 623-646.
16. Luo, G., Qato, M. K., and Guenthner, T. M. (1992). Hydrolysis of the 2′,3′-allylic epoxides of allylbenzene, estragole, eugenol, and safrole by both microsomal and cytosolic epoxide hydrolases. Drug Metab. Dispos. 20, 440-445.
17. Lupfert, C., and Reichel, A. (2005). Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem. Biodivers. 2, 1462-1486.
18. Medinsky, M. A., Leavens, T. L., Csanady, G. A., Gargas, M. L., and Bond, J. A. (1994). In vivo metabolism of butadiene by mice and rats: A comparison of physiological model predictions and experimental data. Carcinogenesis 15, 1329-1340.
19. Miller, E. C., Swanson, A. B., Phillips, D. H., Fletcher, T. L., Liem, A., and Miller, J. A. (1983). Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 43, 1124-1134.
20. Pelkonen, O., and Raunio, H. (1997). Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ. Health Perspect. 105(Suppl. 4), 767-774.
21. Phillips, D. H., Miller, J. A., Miller, E. C., and Adams, B. (1981). Structures of the DNA adducts formed in mouse liver after administration of the proximate hepatocarcinogen 1′-hydroxyestragole. Cancer Res. 41, 176-186.
22. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. II. Newborn male B6C3F1 mice. Carcinogenesis 5 1623-1628.
23. 2-(trans-Isoestragol-3′-yl -2′-deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1′-hydroxyestragole. Chem. Res. Toxicol. 20, 991-998.
24. Punt, A., Freidig, A. P., Delatour, T., Scholz, G., Boersma, M. G., Schilter, B., Van Bladeren, P. J., and Rietjens, I. M. C. M. (2008). A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicol. Appl. Pharmacol. 231, 248-259.
25. Quick, D. J., and Shuler, M. L. (1999). Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol. Prog. 15, 540-555.
26. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice. Carcinogenesis 5 1613-1622.
27. 14C]-labeled trans-anethole, estragole and p-propylanisole in human volunteers. Xenobiotica 17, 1223-1232.
28. Scientific Committee on Food (SCF). (2001). Opinion of the scientific committee on food on estragole (1-allyl-4-methyxybenzene). Available at: http://ec.europa.eu/food/fs/sc/scf/out104_en.pdf. Accessed May 29, 2009.
29. Shimada, T., Yamazaki, H., Mimura, M., Wakamiya, N., Ueng, Y., Genguerich, F. P., and Inui, Y. (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24, 515-522.
30. Smith, R. L., Adams, T. B., Doull, J., Feron, V. J., Goodman, J. I., Marnett, L. J., Portoghese, P. S., Waddell, W. J., Wagner, B. M., Rogers, A. E., et al. (2002). Safety assessment of allylalkoxybenzene derivatives used as flavouring substances - Methyl eugenol and estragole. Food Chem. Toxicol. 40, 851-870.
31. Solheim, E., and Scheline, R. R. (1973). Metabolism of alkenebenzene derivatives in the rat I. p-Methoxyallylbenzene (estragole) and p-methoxypropenylbenzene (anethole). Xenobiotica 3, 493-510.
32. Wiester, M. J., Winsett, D. W., Richards, J. H., Doerfler, D. L., and Costa, D. L. (2002). Partitioning of benzene in blood: Influence of hemoglobin type in humans and animals. Environ. Health Perspect. 110, 255-261.
33. Wiseman, R. W., Fennell, T. R., Miller, J. A., and Miller, E. C. (1985). Further characterization of the DNA adducts formed by electrophilic esters of the hepatocarcinogens 1′-hydroxysafrole and 1′-hydroxyestragole in vitro and in mouse liver in vivo, including new adducts at C-8 and N-7 of guanine residues. Cancer Res. 45, 3096-3105.
34. Wiseman, R. W., Miller, E. C., Miller, J. A., and Liem, A. (1987). Structure-activity studies of the hepatocarcinogenicities of alkenylbenzene derivatives related to estragole and safrole on administration to preweanling male C57BL/6J x C3H/HeJ F1mice. Cancer Res. 47, 2275-2283.
35. Wislocki, P. G., Miller, E. C., Miller, J. A., McCoy, E. C., and Rosenkranz, H. S. (1977). Carcinogenic and mutagenic activities of safrole, 1′-hydroxysafrole, and some known or possible metabolites. Cancer Res. 37, 1883-1891.
36. Zangouras, A., Caldwell, J., Hutt, A. J., and Smith, R. L. (1981). Dose dependent conversion of estragole in the rat and mouse to the carcinogenic metabolite, 1′-hydroxyestragole. Biochem. Pharmacol. 30, 1383-1386.